TY - JOUR
T1 - Bortezomib is effective to treat acute humoral rejection after liver transplantation
AU - Lee, C. F.
AU - Eldeen, F. Z.
AU - Chan, Kun-Ming
AU - Wu, T. H.
AU - Soong, Ruey-Shyang
AU - Wu, T. J.
AU - Chou, H. S.
AU - Lee, Wei-Chen
PY - 2012/3
Y1 - 2012/3
N2 - Introduction: Acute humoral rejection (AHR), a rare complication in orthotopic liver transplantation (OLT), responds poorly to conventional therapies. Bortezomib, a proteasome inhibitor, has been shown to be effective in treating plasma cellderived tumors and acute rejection episodes after renal transplantation. Herein, we have reported our clinical experience with bortezomib as a novel approach to treat AHR after OLT. Methods: We retrospectively analyzed the 247 adult OLTs performed from January 2007 to April 2011. Patients with AHR who were treated with steroid pulses, rituximab (375 mg/m 2), and plasmapheresis (PP) were assigned to group A. Group B subjects were prescribed steroid pulses, rituximab, PP, and bortezomib (1.3 mg/m 2), after March 2009. Results: Among the 9 patients (3.6%) diagnosed with AHR, all subjects in group A (n = 3) died within several days after AHR, whereas 4/6 (66.7%) group B patients were rescued and 3 (50%) survived at a mean follow-up 22.3 months (range, 1826). Conclusion: Proteasome inhibitor-based therapies provide a more effective strategy to treat AHR after OLT.
AB - Introduction: Acute humoral rejection (AHR), a rare complication in orthotopic liver transplantation (OLT), responds poorly to conventional therapies. Bortezomib, a proteasome inhibitor, has been shown to be effective in treating plasma cellderived tumors and acute rejection episodes after renal transplantation. Herein, we have reported our clinical experience with bortezomib as a novel approach to treat AHR after OLT. Methods: We retrospectively analyzed the 247 adult OLTs performed from January 2007 to April 2011. Patients with AHR who were treated with steroid pulses, rituximab (375 mg/m 2), and plasmapheresis (PP) were assigned to group A. Group B subjects were prescribed steroid pulses, rituximab, PP, and bortezomib (1.3 mg/m 2), after March 2009. Results: Among the 9 patients (3.6%) diagnosed with AHR, all subjects in group A (n = 3) died within several days after AHR, whereas 4/6 (66.7%) group B patients were rescued and 3 (50%) survived at a mean follow-up 22.3 months (range, 1826). Conclusion: Proteasome inhibitor-based therapies provide a more effective strategy to treat AHR after OLT.
UR - https://www.scopus.com/pages/publications/84863258204
U2 - 10.1016/j.transproceed.2012.01.051
DO - 10.1016/j.transproceed.2012.01.051
M3 - 文章
C2 - 22410063
AN - SCOPUS:84863258204
SN - 0041-1345
VL - 44
SP - 529
EP - 531
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 2
ER -